Navigation Links
Spectranetics Receives Reimbursement Approval in Belgium for Lead Removal and Peripheral Atherectomy Products
Date:10/9/2007

COLORADO SPRINGS, Colo., Oct. 9 /PRNewswire-FirstCall/ -- Spectranetics Corporation (Nasdaq: SPNC) today announced it has received reimbursement approval from the competent governmental authority in Belgium for its lead removal and peripheral atherectomy product line, effective October 1, 2007.

The reimbursement for the lead removal indication -- an embedded, infected lead or an electronic malfunction of a pacemaker or defibrillator electrode -- applies to hospitals in Belgium that meet the national cardiac pathology requirements and standards. The reimbursement for the peripheral indication applies to all centers in Belgium equipped with Spectranetics' technology for patients that suffer from critical limb ischemia with non-healing ulcers or rest pain due to infrapopliteal disease.

Shar Matin, Managing Director of Spectranetics International, B.V. commented, "We are very pleased that the Belgian authority granted reimbursement approval for our laser-based therapies. Belgian patients now have greater access to our life-changing technology. Reimbursement initiatives are a cornerstone of Spectranetics International's strategy and this approval follows the reimbursement approval in Germany for our peripheral atherectomy device earlier this year."

About Spectranetics

Founded in 1984, Spectranetics manufactures and sells the only excimer laser approved in the United States, Europe and Japan for use in minimally invasive cardiovascular procedures. This technology treats complex cardiovascular conditions by photo-ablating multiple lesion types into tiny particles that are easily absorbed into the blood stream. The Company's disposable catheters use high-energy "cool" ultraviolet light to vaporize arte
'/>"/>

SOURCE Spectranetics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Infant receives first bloodless liver transplant
2. British MPs Say Prostate Cancer Receives Low Priority in the NHS
3. Fifth US Patient Receives Artificial Heart
4. Northfield Labs Receives FDA Comments
5. Abbott Receives CE Mark Certification
6. Zactima Receives Fast Track Designation By The FDA
7. East London Receives World Class New Private Hospital Facility
8. Brinda Karat Receives Legal Notice over Ramdev Issue
9. Quake-Hit Pakistan Receives 30 Field Hospitals From Cuba
10. Medtronic’s Insulin Pump Receives Regulatory Approva
11. Aurobindo Receives Approval from USFDA for anti-AIDS drug
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Discover Health Through Awareness 2Discover Health Through Awareness 3Amber Pharmacy Earns Accreditation From ACHC 2Houston Northwest Medical Centers Bariatric Program Rated Top 15 25 in the Nation by HealthGrades 52902 1Houston Northwest Medical Centers Bariatric Program Rated Top 15 25 in the Nation by HealthGrades 52902 2Houston Northwest Medical Centers Bariatric Program Rated Top 15 25 in the Nation by HealthGrades 52902 3Cynosure Reports Second Quarter 2009 Financial Results 13226 1Cynosure Reports Second Quarter 2009 Financial Results 13226 2Cynosure Reports Second Quarter 2009 Financial Results 13226 3Cynosure Reports Second Quarter 2009 Financial Results 13226 4Cynosure Reports Second Quarter 2009 Financial Results 13226 5Cynosure Reports Second Quarter 2009 Financial Results 13226 6Cynosure Reports Second Quarter 2009 Financial Results 13226 7Cynosure Reports Second Quarter 2009 Financial Results 13226 8Cynosure Reports Second Quarter 2009 Financial Results 13226 9Cynosure Reports Second Quarter 2009 Financial Results 13226 10Cynosure Reports Second Quarter 2009 Financial Results 13226 11Cynosure Reports Second Quarter 2009 Financial Results 13226 12Cynosure Reports Second Quarter 2009 Financial Results 13226 13QLT announces interim data from a Phase II clinical trial and a device study for the Punctal Plug Drug Delivery System 52896 1QLT announces interim data from a Phase II clinical trial and a device study for the Punctal Plug Drug Delivery System 52896 2QLT announces interim data from a Phase II clinical trial and a device study for the Punctal Plug Drug Delivery System 52896 3QLT announces interim data from a Phase II clinical trial and a device study for the Punctal Plug Drug Delivery System 52896 4QLT announces interim data from a Phase II clinical trial and a device study for the Punctal Plug Drug Delivery System 52896 5QLT announces interim data from a Phase II clinical trial and a device study for the Punctal Plug Drug Delivery System 52896 6QLT announces interim data from a Phase II clinical trial and a device study for the Punctal Plug Drug Delivery System 52896 7